MET and non-small cell lung carcinoma: Telisotuzumab vedotin (Teliso-V) is a c-Met-directed immunoconjugate with an MMAE cytotoxic payload, which produced durable responses as monotherapy in c-MET-overexpressing NSCLC with a wildtype EGFR gene.